H
Hans-Peter Horny
Researcher at Ansbach
Publications - 118
Citations - 4737
Hans-Peter Horny is an academic researcher from Ansbach. The author has contributed to research in topics: Systemic mastocytosis & Bone marrow. The author has an hindex of 37, co-authored 100 publications receiving 4316 citations. Previous affiliations of Hans-Peter Horny include University of Kiel & University of Tübingen.
Papers
More filters
Journal ArticleDOI
Contemporary consensus proposal on criteria and classification of eosinophilic disorders and related syndromes.
Peter Valent,Amy D. Klion,Hans-Peter Horny,Florence Roufosse,Jason Gotlib,Peter F. Weller,Andrzej Hellmann,Georgia Metzgeroth,Kristin M. Leiferman,Michel Arock,Joseph H. Butterfield,Wolfgang R. Sperr,Karl Sotlar,Peter Vandenberghe,Torsten Haferlach,Hans-Uwe Simon,Andreas Reiter,Gerald J. Gleich +17 more
TL;DR: In the year 2011 Working Conference on Eosinophil disorders and Syndromes, a panel of experts from the fields of immunology, allergy, hematology, and pathology contributed to this project as mentioned in this paper.
Journal ArticleDOI
Definitions and standards in the diagnosis and treatment of the myelodysplastic syndromes: Consensus statements and report from a working conference
Peter Valent,Hans-Peter Horny,John M. Bennett,Christa Fonatsch,Ulrich Germing,Peter L. Greenberg,Torsten Haferlach,Detlef Haase,H. J. Kolb,Otto Krieger,Michael R. Loken,Arjan A. van de Loosdrecht,Kiyoyuki Ogata,Alberto Orfao,Michael Pfeilstöcker,Björn Rüter,Wolfgang R. Sperr,Reinhard Stauder,Denise A. Wells +18 more
TL;DR: Concerning the diagnostic interface, minimal diagnostic criteria for MDS are proposed, and for patients with unexplained cytopenia who do not fulfill these criteria, the term 'idiopathic cy topenia of uncertain significance' (ICUS) is suggested.
Journal ArticleDOI
Bone marrow findings in systemic mastocytosis.
TL;DR: On the basis of the hematologic and clinical findings, chronic myeloids leukemia was diagnosed in six of these cases, myelomonocytic leukemia in three cases, and acute myeloid leukemia in two cases.
Journal ArticleDOI
Mastocytosis: state of the art.
TL;DR: Most patients with mastocytosis remain in an indolent stage over many years or even decades, while others, in particular those with aggressive SM, SM-AHNMD, or mast cell leukemia, show a progressive course, usually with a fatal outcome.
Journal ArticleDOI
Diagnostic value of immunostaining for tryptase in patients with mastocytosis.
Hans-Peter Horny,Christian Sillaber,David M. Menke,Edwin Kaiserling,Manfred Wehrmann,Birgitta Stehberger,Andreas Chott,Klaus Lechner,Karl Lennert,Peter Valent +9 more
TL;DR: Tissue sections from 93 patients with mastocytosis were stained with antitryptase antibody G3, and tryptase, Giemsa, and CAE produced diagnostic staining of MCs in virtually all cases of systemic indolent mastocyTosis, urticaria pigmentosa, and solitary skinmastocytoma.